Wellgistics Launches Forzet(TM) to Address Muscle Loss from GLP-1 Drugs

New medical food targets $70B GLP-1 agonist market to help patients maintain muscle while on weight loss therapies.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Wellgistics Health, Inc. has announced the launch of Forzet(TM), a medical food product for the dietary management of muscle loss associated with weight loss therapies, particularly those involving GLP-1 agonist drugs like Ozempic(R), Wegovy(R), and Mounjaro(R). Forzet is intended to help preserve muscle mass while patients are on GLP-1 therapy and facilitate muscle redevelopment after discontinuing the drugs, in order to mitigate potential weight regain.

Why it matters

The GLP-1 agonist market is expected to grow from $70 billion in 2025 to $201 billion in 2030, driven by the increasing potency of these drugs to induce weight loss. However, muscle loss is a common side effect, which can limit patient adherence and lead to weight regain. Forzet aims to address this issue by providing a clinically-evaluated solution to help patients maintain muscle mass.

The details

Forzet is classified as a medical food intended for the dietary management of muscle loss associated with weight loss therapies under physician supervision. It will initially be available through Wellgistics' affiliated pharmacy and select members of its Pharmacy Network. Wellgistics plans to integrate Forzet into its EinsteinRx hub technology to recommend it as an adjunct solution for patients prescribed GLP-1 agonist drugs, and to feature it as a central part of the company's direct-to-consumer telehealth offerings.

  • Forzet was announced for launch on March 9, 2026.

The players

Wellgistics Health, Inc.

A health information technology leader that is integrating its proprietary pharmacy dispensing optimization AI platform EinsteinRx(TM) and blockchain-enabled smart contracts platform PharmacyChain(TM) to optimize the prescription drug dispensing journey.

Forzet(TM)

A medical food product developed by Wellgistics for the dietary management of muscle loss associated with weight loss therapies.

Ozempic(R), Wegovy(R), Mounjaro(R)

GLP-1 agonist drugs that are members of the fastest growing class of drugs worldwide due to their ability to induce weight loss.

Dr. Vivek Bansal, MD MPH

A triple board-certified endocrinologist and founder of The EnLyv Clinics in Bridgewater, NJ, who has been working to address muscle loss in patients on weight loss therapies and believes Forzet represents a unique solution.

Prashant Patel, RPh

The President & Interim-CEO of Wellgistics Health.

Got photos? Submit your photos here. ›

What they’re saying

“Forzet is indicated for the dietary management of muscle loss associated with weight loss therapies.”

— Prashant Patel, President & Interim-CEO of Wellgistics Health

“We have been working through myriad products seeking to address muscle loss while on current weight loss therapies, and believe Forzet represents a unique solution that has worked well in other sarcopenia-related medical conditions. We are excited to make this available to our patients.”

— Dr. Vivek Bansal, Triple Board-Certified Endocrinologist and Founder of The EnLyv Clinics

What’s next

Wellgistics plans to leverage Forzet's unique value proposition by recommending it as an adjunct solution for patients prescribed GLP-1 agonist drugs via pop-ups through its EinsteinRx hub technology at the point-of-sale in Wellgistics Pharmacy Network pharmacies. The company also intends to make GLP-1 drug and related solutions like Forzet a central feature of its direct-to-consumer telehealth offerings as it expands those efforts.

The takeaway

Forzet represents a clinically-evaluated medical food solution to help address a key side effect of the rapidly growing GLP-1 agonist drug class - muscle loss - which can limit patient adherence and lead to weight regain. By preserving muscle mass, Forzet aims to facilitate continued use of these effective weight loss therapies and support long-term health outcomes.